Regeneron drops after skin cancer treatment misses late-stage trial goal

Shares of Regeneron fell 11.8% premarket on Monday after the company's ​experimental treatment missed the main goal in ‌a late-stage trial in patients with advanced melanoma, a type of skin cancer....

Reuters - 5/18/2026 5:57:56 AM More News for REGN
Stock Analysis for REGN
Related Stocks: